• Home
• Reports
• Companies

• Partnering Search
• Profiling
• Deal Negotiation

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deals review
• Industry news

• Press releases
• Events
• Newsletter

American Conference Institute’s 7th National Conference on Life Sciences IP Due Diligence

Summary

20 Jan 2010-22 Jan 2010 — New York, United States

Your complete guide to M&As, licensing, and other collaborations for the pharmaceutical, biotechnology and medical device Industries.

Contact details

Joanna Christopoulos email: wougene@aci-ny.com phone: +1.888.224.2480

Venue

— 20 Jan Wed-12:00 22 Jan 2010

AVOID PUTTING YOUR NEXT DEAL AT RISK

Now is the time to revisit your IP due diligence review protocol to ensure your company possesses the necessary tools to conduct a thorough, comprehensive and accurate review.

Learn directly from the experts ACI's7th National Life Sciences IP Due Diligence Conference
Your Complete Guide to M&As, Licensing, and Other Collaborations for the Pharmaceutical, Biotechnology and Medical Device Industries

Within the life sciences industries, IP is THE driving force behind a deal. Whether negotiating a merger, collaboration or licensing agreement, your diligence review team must be confident that there will be no impediments to commercializing the IP that is being gained as part of the deal.

Every stone must be turned during a diligence review. As such, when conducting the review, your team must be able to make an informed decision regarding how the IP at issue will increase the company's overall value, whether by expanding a product line or opening the door to emergence in a new market.

As companies consider the impact of developing case law affecting IP in the life sciences industries, as well as proposed follow-biologic and patent reform legislation, now is the time to consider how emerging changes in the patent and regulatory landscape could modify the manner in which IP transactions are handled within your industry.

Don't miss this opportunity to learn directly from experienced IP and patent practitioners in the pharmaceutical, biotechnology and medical device industries while benchmarking your current practices against those of the leading companies in your industry. For more information and to view the full agenda, please visit: www.americanconference.com/Diligence